This renewal application requests funding for the continuation of the Southwest Oncology Group Clinical Trials Cooperative Grant at City of Hope (COH) for years 23-28. The COH faculty has a longstanding commitment to the Southwest Oncology Group as demonstrated by their leadership in the group, involvement in protocol development, meeting attendance, and enrollment of patients on SWOG studies. Dr. Steven Forman has chaired the BMT Committee since 1993 and pilot studies first tested at City of Hope have been incorporated into treatment arms on SWOG trials. Many of our faculty are Principal Investigators on SWOG trials and our annual enrollment to SWOG studies exceeds 100 patients per year. Our faculty involvement spans many disciplines including Medical Oncology, General Surgical Oncology, Urology, Pathology, Pharmacy and Pharmacology who serve on critical committees and enroll patients on clinical trials. SWOG members from COH also contribute substantially to research activities in oncologic surgery and cancer prevention. Substantive scientific patient accrual to SWOG clinical trials by the COH can be predicted to continue over the coming funding cycle. Our faculty have authored numerous publications. Clinical research through the Southwest Oncology Group continues to be an important part of the COH research portfolio. Recognizing the importance of SWOG to the institution, City of Hope supports the regulatory, data collection, and quality assurance infrastructure that is not entirely supported by the current grant. We anticipate that our participation in SWOG will continue to grow as our institution expands both on the main Duarte campus and with our burgeoning affiliate program.
City of Hope recognizes the improved quality of patient care that is associated with participation in clinical trials. The institution is committed to enrolling our diverse population of patients on SWOG clinical trials.
|Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231|
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2017) A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol :|
|Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21|
Showing the most recent 10 out of 149 publications